Clinical Trial Update: Everolimus on CKD Progression in ADPKD Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial of everolimus for slowing CKD progression in autosomal dominant polycystic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: A. Manzoni Hospital | Conditions: Polycystic Kidney Diseases | Phase 2, Phase 3 | Status: TERMINATED